Comparing de novo and relapse stages of AML, Wakita et al demonstrated that mutations in the epigenetic modification genes (DNMT3A, TET2 and IDH) are stably present at diagnosis and relapse suggesting them as potential biomarker in minimal residual disease (MRD) monitoring [75]. This evidence concerns the gene IDH1 and acute myeloid leukemia.